Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advil Migraine Liqui-Gels

This article was originally published in The Tan Sheet

Executive Summary

Whitehall-Robins receives FDA approval for the indication-specific OTC analgesic March 16. Approved under NDA 20-402/S-005, the product is the third nonprescription migraine pain reliever to be cleared by the agency, putting it in a race to market with McNeil Consumer Healthcare's Motrin Migraine Pain, approved Feb. 25 (1"The Tan Sheet" March 6, p. 3). FDA authorized a migraine pain indication for Bristol-Myers Squibb's Excedrin Migraine in January 1998. Advil Migraine Liqui-Gels will contain 200 mg solubolized ibuprofen in liquid-filled capsules and will come in 20-, 40- and 80-count sizes. Labeling will carry the claim "Treats migraine," which Whitehall says applies to migraine symptoms such as nausea and sensitivity to light and sound. The company believes Motrin's approved claim - "Treats pain of migraine headache" - to be more restrictive
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS090976

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel